NEFL and myeloid sarcoma: Currently, the two most promising biomarker candidates for assessing neural damage in MS patients are NFL and GFAP; however, results are inconsistent across studies, which is highly suggestive of the variability in techniques used to measure them, as well as the heterogeneity across study cohorts [34].